Abstract
Inflammatory bowel disease (IBD) is a chronic intestinal disease associated with the inflammatory gastrointestinal tract and microbiome dysbiosis. Probiotics are a promising intervention, and several probiotics have been reported to positively affect IBD remission and prevention, particularly on ulcerative colitis (UC). However, there is still a limitation in the knowledge of effectiveness and safety of probiotics therapies for IBD. Exploring more potential probiotics helps to find extensive evidence for probiotic intervention. This study established a rapid method for probiotics candidate screening and finally screened out one strain with the best protective effect. Forty strains isolated from four different sources were used for this screening. Hemolysis tests and acute toxic test evaluated strain safety. Zebrafish were first treated with dextran sodium sulfate (DSS) for colitis induction, and every bacteria were individually added to the fish water subsequently. Results showed eight strains could lower the larvae mortality within 3 days under a 0.6% DSS concentration, including Lacticaseibacillus rhamnosus GG, L. rhamnosus NBRC3425, Bacillus smithii DSM4216, B. smithii XY1, Bacillus coagulans NBRC12583, Bacillus coagulans XY2, Lactobacillus parafarraginis XYRR2, and Bacillus licheniformis XYT3. Among eight, B. smithii XY1 was the only strain having the equal ability to alleviate neutrophil infiltration in the larvae intestine with that ability of prednisolone under a 0.5% DSS concentration. Bacillus smithii XY1 restored intestinal epithelial cell integrity after DSS damage, as well as regulated the gene expression inflammation-related factors, indicating its bio-function of inflammatory response alleviation.
Highlights
Inflammatory bowel diseases (IBD), types of chronic intestinal diseases characterized by immunemediated intestinal inflammation of the gastrointestinal tract, affect millions of people every year (Ng et al, 2017)
The strains isolation strategy and the potential probiotics strain library were constructed as the implementation: a
A rapid and preliminary bacteria screening approach for IBD remission was designed for this work
Summary
Inflammatory bowel diseases (IBD), types of chronic intestinal diseases characterized by immunemediated intestinal inflammation of the gastrointestinal tract, affect millions of people every year (Ng et al, 2017). Probiotic Screening Aimed at IBD that IBD has become a global disease in the 21st century (Ananthakrishnan et al, 2020). Normal intestinal microbial flora is vital for the host to maintain the gut’s well-being and integrity of gut immunity (Zareef et al, 2020). The alteration of normal gut microbiota in the patients contributes to IBD incidence (Zareef et al, 2020). Fecal microbiota transplantation (FMT) has been proved available in Clostridium difficile infection and in some IBD clinical trials (Friedman et al, 2014; Browne and Kelly, 2017). Further evidence is needed before FMT or probiotics could be used in practice treatment, and probiotic or prebiotic therapies could be the step (Friedman et al, 2014)
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
